Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882687 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00882687 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 60 participants.
The verdict
NCT00882687, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
Interventions
- OTHER Placebo
- DRUG Lifitegrast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-04-24 |
| Est. Completion | 2009-05-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882687
The ClinicalTrials.gov registry entry for NCT00882687 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00882687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882687 about?
NCT00882687 is a clinical study titled "Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis". The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
What is the current status of trial NCT00882687?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2009-04-24. Estimated completion is 2009-05-10.
What interventions are being tested in trial NCT00882687?
The interventions under investigation include: Placebo (OTHER), Lifitegrast (DRUG).
Who is sponsoring clinical trial NCT00882687?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.